JP2022533418A5 - - Google Patents
Info
- Publication number
- JP2022533418A5 JP2022533418A5 JP2021569109A JP2021569109A JP2022533418A5 JP 2022533418 A5 JP2022533418 A5 JP 2022533418A5 JP 2021569109 A JP2021569109 A JP 2021569109A JP 2021569109 A JP2021569109 A JP 2021569109A JP 2022533418 A5 JP2022533418 A5 JP 2022533418A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- nos
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852039P | 2019-05-23 | 2019-05-23 | |
| US62/852,039 | 2019-05-23 | ||
| PCT/US2020/034281 WO2020237173A1 (en) | 2019-05-23 | 2020-05-22 | Anti-ror1/anti-cd3 bispecific binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533418A JP2022533418A (ja) | 2022-07-22 |
| JP2022533418A5 true JP2022533418A5 (enExample) | 2023-05-24 |
| JP7611171B2 JP7611171B2 (ja) | 2025-01-09 |
Family
ID=71078637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569109A Active JP7611171B2 (ja) | 2019-05-23 | 2020-05-22 | 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12655217B2 (enExample) |
| EP (1) | EP3972999A1 (enExample) |
| JP (1) | JP7611171B2 (enExample) |
| KR (1) | KR20220012313A (enExample) |
| CN (1) | CN113874399B (enExample) |
| AU (1) | AU2020277489A1 (enExample) |
| BR (1) | BR112021023026A2 (enExample) |
| CA (1) | CA3139111A1 (enExample) |
| MX (1) | MX2021014193A (enExample) |
| TW (1) | TWI899079B (enExample) |
| WO (1) | WO2020237173A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4069735A1 (en) * | 2019-12-06 | 2022-10-12 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 bispecific antibody constructs |
| BR112022015416A2 (pt) * | 2020-02-07 | 2022-10-11 | Velosbio Inc | Anticorpos anti-ror1 e composições |
| JP7858665B2 (ja) * | 2021-02-02 | 2026-05-14 | ヌマブ セラピューティックス アーゲー | Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| WO2023000791A1 (en) * | 2021-07-23 | 2023-01-26 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| EP4384218A4 (en) * | 2021-08-09 | 2025-11-05 | Merck Patent Gmbh | Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines |
| US20250051443A1 (en) * | 2021-10-07 | 2025-02-13 | National Research Council Of Canada | Anti-cd3 monoclonal antibodies and therapeutic constructs |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| CN105073128A (zh) | 2013-04-03 | 2015-11-18 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| MX386342B (es) * | 2014-07-25 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Móleculas de unión a her2 y cd3 biespecíficas. |
| EP3204415B1 (en) * | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3091032A1 (en) * | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
| EP3851457A1 (en) * | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| CA3011419A1 (en) * | 2016-01-22 | 2017-07-27 | Janssen Biotech, Inc. | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same |
| AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| TWI804499B (zh) * | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| BR112022015416A2 (pt) * | 2020-02-07 | 2022-10-11 | Velosbio Inc | Anticorpos anti-ror1 e composições |
-
2020
- 2020-05-22 KR KR1020217041982A patent/KR20220012313A/ko not_active Withdrawn
- 2020-05-22 CN CN202080038180.6A patent/CN113874399B/zh active Active
- 2020-05-22 US US17/613,251 patent/US12655217B2/en active Active
- 2020-05-22 MX MX2021014193A patent/MX2021014193A/es unknown
- 2020-05-22 EP EP20732061.5A patent/EP3972999A1/en active Pending
- 2020-05-22 CA CA3139111A patent/CA3139111A1/en active Pending
- 2020-05-22 TW TW109117258A patent/TWI899079B/zh active
- 2020-05-22 WO PCT/US2020/034281 patent/WO2020237173A1/en not_active Ceased
- 2020-05-22 BR BR112021023026A patent/BR112021023026A2/pt unknown
- 2020-05-22 JP JP2021569109A patent/JP7611171B2/ja active Active
- 2020-05-22 AU AU2020277489A patent/AU2020277489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| CN109071666B (zh) | 人脊髓灰质炎病毒受体(pvr)特异性抗体 | |
| US20190144540A1 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| JP2022526764A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| WO2019214624A1 (en) | Fully human antibodies against ox40, method for preparing same, and use thereof | |
| ME02377B (me) | Anti-igf antitijela | |
| JP7692422B2 (ja) | 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用 | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2023518153A5 (enExample) | ||
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| CN112625128B (zh) | 抗ngf抗体及其抗原结合片段、其制备方法和应用 | |
| JP2022532991A5 (enExample) | ||
| JP2025513721A5 (enExample) | ||
| JP2025513593A5 (enExample) | ||
| JP2022550327A (ja) | 新規の抗ｐｄ－ｌ１抗体 | |
| WO2021057930A1 (en) | A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2021516670A (ja) | 抗ｔｒａｉｌｒ２抗体−毒素−複合体およびその抗腫瘍治療における薬物用途 | |
| WO2021169986A1 (en) | A bifunctional fusion protein and uses thereof | |
| JP7196311B2 (ja) | 抗ｔｉｍ－３抗体とその利用 | |
| EP4196500A2 (en) | Cancer treatment methods using anti-cd73 antibodies | |
| CN107106676A (zh) | 用于治疗肉瘤的组合物和方法 | |
| RU2021137832A (ru) | Анти-ror1/анти-cd3 биспецифические связывающие молекулы | |
| CN118047867B (zh) | 一种抗bcma的纳米抗体、抗体及其应用 |